Launched in 1989 in France, Dotarem® is currently available in over 70 countries.
Dotarem® is licensed for patients of all ages for enhancement of contrast for Encephalic and spinal MRI, whole body MRI (including cardiac, breast, uterine, ovarian, abdominal, renal, and osteo-articular pathology) and for adults (18 year and above) in angiography16.
Nephrogenic Systemic Fibrosis (NSF) is a well-documented concern in MRI. Dotarem has no confirmed unconfounded cases of NSF17. According to the FDA and EMA, Dotarem has a low-level risk for NSF18.